Get the Stockscreener App
12.56
0.56%
0.07
After Hours:
12.56
Contineum Therapeutics Inc stock is traded at $12.56, with a volume of 404.93K.
It is up +0.56% in the last 24 hours and down -26.33% over the past month.
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.
See More
Previous Close:
$12.49
Open:
$12.57
24h Volume:
404.93K
Relative Volume:
0.80
Market Cap:
$472.52M
Revenue:
$50.00M
Net Income/Loss:
$-58.44M
P/E Ratio:
-6.4321
EPS:
-1.9527
Net Cash Flow:
$-57.73M
1W Performance:
-7.17%
1M Performance:
-26.33%
6M Performance:
-5.42%
1Y Performance:
+15.65%
1-Day Range:
$12.10
$12.88
1-Week Range:
$11.40
$14.00
52-Week Range:
$8.60
$17.79
Contineum Therapeutics Inc Stock (CTNM) Company Profile
Name
Contineum Therapeutics Inc
Sector
Industry
Phone
(858) 333-5280
Address
3565 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO
Compare CTNM vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CTNM
Contineum Therapeutics Inc
|
12.56 | 472.52M | 50.00M | -58.44M | -57.73M | -1.9527 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Contineum Therapeutics Inc Stock (CTNM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-08-26 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-13-25 | Initiated | Leerink Partners | Outperform |
| Sep-25-25 | Initiated | Leerink Partners | Outperform |
| Jun-20-25 | Initiated | William Blair | Outperform |
| Oct-22-24 | Initiated | Robert W. Baird | Outperform |
| Apr-30-24 | Initiated | Morgan Stanley | Overweight |
| Apr-30-24 | Initiated | RBC Capital Mkts | Outperform |
| Apr-30-24 | Initiated | Stifel | Buy |
View All
Contineum Therapeutics Inc Stock (CTNM) Latest News
J&J and Contineum’s Depression Drug Missed Phase 2 Goal. What Comes Next? - Yahoo Finance
Wall Street Analysts Are Bullish on Top Healthcare Picks - theglobeandmail.com
Goldman Sachs initiates coverage on Contineum Therapeutics stock By Investing.com - Investing.com Nigeria
Goldman Sachs initiates coverage on Contineum Therapeutics stock - Investing.com
RBC Capital Sticks to Their Buy Rating for Contineum Therapeutics, Inc. Class A (CTNM) - The Globe and Mail
RBC Cuts Price Target on Contineum Therapeutics to $21 From $23, Keeps Outperform, Speculative Risk - marketscreener.com
Contineum Therapeutics, Inc.(NasdaqGS:CTNM) added to S&P Pharmaceuticals Select Industry Index - marketscreener.com
Analysts Offer Insights on Healthcare Companies: Contineum Therapeutics, Inc. Class A (CTNM) and Definium Therapeutics (DFTX) - theglobeandmail.com
LifeSci Capital Maintains Contineum Therapeutics(CTNM.US) With Buy Rating, Maintains Target Price $23 - Moomoo
Precision Trading with Contineum Therapeutics Inc. (CTNM) Risk Zones - Stock Traders Daily
CTNM Q2 2026 Earnings: Narrower-Than-Expected Loss Lifts Shares 5.32%Revenue Guidance Range - careplusvn.com
Contineum Therapeutics Tumbles After Depression Drug Misses Primary Goal in Phase 2 - finance.biggo.com
Contineum fails in MDD; Definium’s LSD prospect nears NDA - BioWorld News
Johnson & Johnson Partner Contineum Slides as Depression Drug Fails - Yahoo Finance
JonesTrading Maintains Contineum Therapeutics(CTNM.US) With Buy Rating, Cuts Target Price to $24 - Moomoo
Stifel maintains Buy on Contineum stock after phase 2 trial miss - Investing.com Canada
Contineum’s depression drug trial fails primary endpoint By Investing.com - Investing.com India
Contineum Therapeutics Shares Fall After Drug Trial Missed Primary Endpoint - marketscreener.com
Contineum Therapeutics Reports Phase 2 MOONLIGHT-1 Results - TipRanks
Contineum Therapeutics stock falls on phase 2 trial miss By Investing.com - Investing.com Australia
Contineum, J&J's depression drug fails to meet mid-stage trial goal - marketscreener.com
Contineum Therapeutics Reports Phase 2 Results for JNJ-5120/PIPE-307 for the Treatment of Major Depressive Disorder - Yahoo Finance
Contineum Therapeutics CEO Stengone sells $41,141 in stock By Investing.com - Investing.com Canada
Contineum Therapeutics CEO Stengone sells $41,141 in stock - Investing.com
Contineum (CTNM) CEO sells shares under preset plan - Stock Titan
Carmine Stengone to sell 2,500 Contineum (CTNM) shares - Stock Titan
Technical Reactions to CTNM Trends in Macro Strategies - Stock Traders Daily
Show Me The Money: Contineum Therapeutics' Turnaround From Lows To New Highs - RTTNews
RBC Capital Maintains Contineum Therapeutics(CTNM.US) With Buy Rating, Maintains Target Price $23 - Moomoo
Contineum Therapeutics (CTNM) Climbs 1.91% as Shares Hold Above Key SupportWyckoff Accumulation - vinanet.vn
Officer at Contineum (NASDAQ: CTNM) lines up new stock sale - Stock Titan
Behavioral Patterns of CTNM and Institutional Flows - Stock Traders Daily
Wall Street Analysts Think Contineum Therapeutics, Inc. (CTNM) Could Surge 49.21%: Read This Before Placing a Bet - qz.com
Contineum Therapeutics to Present at the 2026 Morgan Stanley Global Healthcare Conference - The Chronicle-Journal
Contineum (CTNM) Chart: Records a 7.30% Increase to $17.19 for the Current Session - vinanet.vn
Contineum (CTNM) Chart: Records a 7.30% Increase to $17.19 for the Current Session; Chart View: the Current Price Sits Inside the Supplied Technical Range in the Available RecordVolatility Breakout Picks - siam.in
Balyasny Asset Management L.P. Expands Stake in Contineum Therap - GuruFocus
Contineum (CTNM) Results at a Glance: The Bottom-Line Figure Beats Its Comparison in Latest Trading; Closing Move - vinanet.vn
Morgan Stanley Adjusts PT on Contineum Therapeutics to $18 From $16, Keeps Equalweight Rating - marketscreener.com
Contineum Therapeutics, Inc. Stock 12‑Month Price Target Raised to $23.14, Implies 63% Upside - TradingView
Contineum Therapeutics (CTNM) Slides 7.25% to $14.19 — Testing Key Support After Sharp Sell-OffFair Value Gap - vinanet.vn
Stifel Maintains Contineum Therapeutics(CTNM.US) With Buy Rating, Maintains Target Price $28 - Moomoo
Contineum Therapeutics (NASDAQ:CTNM) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Contineum Therapeutics (NASDAQ:CTNM) Trading Down 4.9%What's Next? - marketbeat.com
Contineum Therapeutics (CTNM): Balyasny group reports 7.14% stake in 13G/A filing - Stock Titan
Contineum Therapeutics (NASDAQ:CTNM) Trading 6.8% HigherShould You Buy? - MarketBeat
CTNM Q2 2026 Earnings: Narrower-Than-Expected Loss Drives Modest Share GainCFO Commentary Report - Vinanet
CTNM Q2 2026 Earnings: Narrower-than-Expected Loss Lifts SharesGross Profit Margin - Vinanet
Contineum Therapeutics (CTNM) Pulls Back 3.66% to $14.49 as Support Level Comes into FocusZero Lag EMA - dars.gov.et
(CTNM) Risk Channels and Responsive Allocation - Stock Traders Daily
Form 4 Contineum Therapeutics Inc For: 3 August By Investing.com - Investing.com Nigeria
Contineum Therapeutics Inc Stock (CTNM) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):